BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $585,467 | +31.8% | 22,202 | -14.0% | 0.00% | 0.0% |
| Q2 2023 | $444,173 | -39.6% | 25,824 | +64.6% | 0.00% | 0.0% |
| Q3 2021 | $735,000 | +55.1% | 15,685 | +101.9% | 0.00% | 0.0% |
| Q2 2021 | $474,000 | -57.0% | 7,768 | -56.6% | 0.00% | -50.0% |
| Q1 2021 | $1,102,000 | +297.8% | 17,890 | +358.6% | 0.00% | – |
| Q4 2020 | $277,000 | +28.2% | 3,901 | -32.1% | 0.00% | – |
| Q3 2020 | $216,000 | -85.8% | 5,749 | -87.7% | 0.00% | -100.0% |
| Q2 2020 | $1,524,000 | – | 46,725 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |